EGFR and non-small cell lung carcinoma: For example, pre-existing EGFR (Epidermal Growth Factor Receptor) inhibitor-resistant cell populations have been observed in vitro within a population of EGFR mutant NSCLC cells, indicating heterogeneity within cancer cell populations, including a transiently maintained “drug tolerant persister” (DTP) subpopulation [2].